Active Ingredient History

  • Now
Crisaborole is a topically administered, boron-containing, anti-inflammatory compound that inhibits the phosphodiesterase-4 (PDE4) activity and thereby suppresses the cytokine release of TNFalpha, IL-12, IL-23 and other cytokines. PDE4 is an an enzyme that converts the intracellular second messenger 3'5'-cyclic adenosine monophosphate (cAMP) into the active metabolite adenosine monophosphate (AMP). By inhibiting PDE4 and thus increasing levels of cAMP, crisaborole controls inflammation. The use of boron chemistry enabled synthesis of a low-molecular-weight compound (251 daltons), thereby facilitating effective penetration of crisaborole through human skin. Crisaborole is in clinical development for the topical treatment of psoriasis and being pursued for the topical treatment of atopic dermatitis. Preliminary studies in children and adults demonstrated favorable efficacy and safety profiles. Crisaborole may represent an anti-inflammatory option that safely minimizes the symptoms and severity of AD and that can be used for both acute and long-term management.   NCATS

  • Mol. Mass: 251.045
  • ALogP: Missing data
  • ChEMBL Molecule:
More Chemistry

Drug Pricing (per unit)

United States

$7.0347 - $10.7294
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

5-(4-cyanophenoxy)-2,3-dihydro-1-hydroxy-2,1-benzoxaborole | an2728 | an-2728 | crisaborole | eucrisa


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue